What happened in the Shaklee-BioCell agreement announced July 21, 2025?
Shaklee Corporation has officially acquired the exclusive licensing rights to Liquid BioCell Collagen from BioCell Technology, LLC, as announced on July 21, 2025. The deal follows Shaklee and Liquid Collagen Acquisition, LLC successfully bidding for the assets of Modere, enabling them to exclusively distribute and market this patented nutritional product. The agreement is effective immediately, and products are available via Shaklee’s ambassador network and its official website.
The announcement was jointly made by Shaklee, BioCell Technology, and Liquid Collagen Acquisition, LLC. Liquid BioCell Collagen is known for its clinically validated support for joint, skin, and connective tissue health, making it a strategic fit for Shaklee’s expanding healthy aging portfolio.
Why is Liquid BioCell Collagen significant to the supplement industry?
Liquid BioCell Collagen has been widely regarded as a gold standard in the collagen supplement category due to its unique bioavailable matrix of hydrolyzed collagen type II, hyaluronic acid, and chondroitin sulfate. Developed and patented by BioCell Technology, it has undergone multiple clinical trials that confirm its efficacy in improving skin hydration, elasticity, and joint comfort.
Shaklee’s acquisition of this licensing right positions it to capitalize on the booming global collagen market, which has witnessed exponential growth in recent years due to consumer demand for anti-aging and mobility support supplements.
BioCell Technology has a long-standing reputation for innovation in the nutricosmetics space, and Liquid BioCell has been one of its flagship ingredients across North America and Asia. The agreement with Shaklee ensures the continued availability and growth of this clinically backed formulation.
How does this acquisition align with Shaklee’s long-term health and wellness strategy?
Roger Barnett, Chairman and CEO of Shaklee Corporation, emphasized that the company’s mission is to help people lead healthier, longer, and more fulfilled lives. Speaking about the deal, he stated that this exclusive licensing of BioCell’s collagen innovation is not merely an acquisition of a product—it is a strategic move to elevate Shaklee’s offerings in every stage of wellness.
The addition of Liquid BioCell to Shaklee’s healthy aging lineup further differentiates the brand in a highly competitive market. The company, which has over six decades of experience in nutritional sciences, plans to integrate Liquid BioCell into its broader product ecosystem while ensuring consistent availability through its direct-selling model.
What was BioCell Technology’s response to the exclusive licensing deal?
BioCell Technology, LLC issued a statement congratulating both Shaklee and Liquid Collagen Acquisition, LLC for securing the rights through a competitive bidding process involving the assets of Modere. The company expressed confidence that Shaklee is the ideal partner to carry forward the legacy and reach of the Liquid BioCell Collagen brand.
The deal also marks a transitional moment for BioCell Technology, as it aligns with a new partner that shares a scientific ethos and commitment to consumer wellness. According to BioCell representatives, this exclusive relationship enables them to extend the commercial potential of Liquid BioCell globally while maintaining quality control and scientific integrity.
What context led to this licensing agreement?
This licensing follows the asset sale involving Modere, a previous distributor of Liquid BioCell Collagen. Modere had positioned the product at the center of its wellness portfolio before entering restructuring proceedings earlier this year. That situation opened a window for other parties to bid for rights associated with Modere’s commercialized products.
Shaklee, along with Liquid Collagen Acquisition, LLC, placed a winning bid for these assets, granting them full commercial and brand control of the Liquid BioCell product line.
The development is part of a wider trend where leading supplement brands are acquiring clinically validated technologies to gain market share in the wellness and anti-aging segments.
Where and how will Shaklee sell the Liquid BioCell Collagen products?
The newly licensed products will be sold through Shaklee’s existing ambassador network and its official e-commerce platform, Shaklee.com. The company’s direct selling model—empowering thousands of independent ambassadors—has been central to its longstanding success.
This model also aligns well with the distribution needs of premium nutraceuticals like Liquid BioCell, which often benefit from consultative sales and consumer education. Shaklee is expected to roll out a full marketing and ambassador support plan to integrate the collagen line seamlessly into its offerings.
What are analysts saying about the strategic value of this move?
Industry observers see this deal as a high-confidence play by Shaklee to solidify its position in the fast-growing collagen and healthy aging markets. Although exact terms of the licensing agreement were not publicly disclosed, the exclusivity attached to Liquid BioCell provides Shaklee with a competitive edge.
Analysts have pointed to the increasing consumer demand for science-backed ingredients as a critical differentiator. Shaklee’s science-driven reputation, paired with the clinical profile of Liquid BioCell, places the company in a strong position to grow its wellness revenue base in both North America and Asia-Pacific.
Moreover, Liquid BioCell’s patented composition and proven results give it an advantage in a crowded collagen space where many offerings lack validation or regulatory oversight.
How does this affect the broader collagen market landscape?
The global collagen market was valued at approximately $5 billion in 2024 and is projected to reach over $8 billion by 2028, according to market research firms. This growth is primarily driven by aging populations, rising interest in cosmetic nutrition, and the demand for mobility and joint health products.
With this licensing, Shaklee becomes one of the few companies to offer an exclusive collagen formulation with proven bioavailability and efficacy. Competitors in the space, such as Vital Proteins and Neocell, primarily sell generic hydrolyzed collagen products that may not offer the same synergistic benefits seen with Liquid BioCell.
Shaklee’s move may prompt rivals to seek similar partnerships or accelerate their own clinical R&D programs to keep pace.
What’s next for Shaklee and BioCell Technology following this deal?
With the exclusive licensing agreement now in effect, Shaklee Corporation is expected to deepen its investment in marketing campaigns that highlight the clinically validated benefits of Liquid BioCell Collagen. Industry watchers anticipate Shaklee will incorporate the ingredient into additional product formats—such as powders, softgels, or beauty-focused formulations—to capture broader segments of the nutraceuticals market. The company may also leverage its digital infrastructure and ambassador network to run targeted campaigns aimed at wellness influencers and health-conscious consumers, especially within the expanding demographic of women over 40—a key growth audience for collagen-based supplements.
BioCell Technology, meanwhile, is likely to focus on product innovation and scientific R&D. Having successfully transferred commercial rights to a trusted industry player, the company may accelerate its development of next-generation ingredients in the joint, skin, and mobility support categories. Strategic collaborations with other research institutes or supplement manufacturers could also be on the horizon, enabling BioCell to diversify its revenue base while preserving scientific credibility.
Both companies are entering a multi-year period of execution, where product availability, consumer education, and clinical validation will play crucial roles in scaling adoption. While no immediate changes to Shaklee’s pricing or ambassador compensation structure have been announced, further strategic updates are expected as the company begins to integrate Liquid BioCell more deeply across its portfolio and customer experience touchpoints.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
